Profound Medical Return on Equity (ROE) Growth & History (PROF)
Profound Medical's return on equity was −67.12% for fiscal 2025.
View full Profound Medical company overviewProfound Medical annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −67.12% | −6.41 pp |
| 2024 | 2024-12-31 | −60.70% | +6.88 pp |
| 2023 | 2023-12-31 | −67.58% | −24.54 pp |
| 2022 | 2022-12-31 | −43.04% | −8.54 pp |
| 2021 | 2021-12-31 | −34.50% | +4.21 pp |
| 2020 | 2020-12-31 | −38.71% | +50.81 pp |
| 2019 | 2019-12-31 | −89.51% | — |
Profound Medical quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −17.47% | +17.39 pp |
| Q1 2026 | 2026-03-31 | −11.21% | +8.08 pp |
| Q4 2025 | 2025-12-31 | −16.58% | −5.79 pp |
| Q3 2025 | 2025-09-30 | −22.34% | — |
| Q2 2025 | 2025-06-30 | −34.86% | — |
| Q1 2025 | 2025-03-31 | −19.29% | — |
| Q4 2024 | 2024-12-31 | −10.80% | — |
Profound Medical return on equity trends
Over the last five fiscal years, Profound Medical's return on equity decreased from −38.71% to −67.12%, a change of −28.41 percentage points. The latest reported quarter, Q2 2026, shows −17.47%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Profound Medical source filings ↗